Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 23, 2018 - Issue 3
Submit an article Journal homepage
525
Views
2
CrossRef citations to date
0
Altmetric
Review

Expert opinion on emerging urate-lowering therapies

Lisa K StampDepartment of Medicine, University of Otago, Christchurch, New ZealandView further author information
,
Tony R MerrimanDepartment of Biochemistry, University of Otago, Dunedin, New ZealandView further author information
&
Jasvinder A SinghMedicine Service, VA Medical Center, Birmingham, AL, USA;Department of Medicine at the School of Medicine, University of Alabama at Birmingham, Birmingham, AL;Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USACorrespondence[email protected]
View further author information
Pages 201-209 | Received 22 Nov 2017, Accepted 20 Sep 2018, Published online: 26 Oct 2018

  • Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310-6. doi: 10.1136/ard.2007.081604. Epub 2008 Jan 4.
  • Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford). 2007;46(9):1441–1444.
  • Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44(8):1038–1042.
  • Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822–829.
  • Khanna D, Fitzgerald J, Khanna P, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. 2012;64(10):1431–1446.
  • Richette P, Doherty M, Pascual E, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016. DOI:10.1136/annrheumdis-2016-209707.
  • Pharmaprojects - copyright to Citeline Drug Intelligence (an informa business) [Internet].
  • Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18(6):876–884.
  • Hosoya T, Sasaki T, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumatol. 2017;36(3):649–656.
  • Hosoya T, Ogawa Y, Hashimoto H, et al. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 2016;41(3):290–297.
  • Choi Y, Larroca V, Lucman A, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties. Arthritis Rheum. 2012;64(10(supple):S697.
  • Saha G, Karpf D, Choi Y, et al. Arhalofenate, a potential novel treatment for hyperuricemia, with or without metabolic co-morbidities, in patients with gout: meta-analysis of urate lowering in four phase 2 studies in type 2 diabetes. Arthritis Rheum. 2011;63(10(suppl)):S1014.
  • McWherter C, Terkeltaub R, Liu-Bryan R. Arhalofenate acid inhibits urate crystal-induced inflammatory responses through activation of AMP-Activated Protein Kinase (AMPK) Signaling [abstract]. Arthritis & rheumatology. 2017 cited 2018 Jan 10;69(suppl 10). Available from. http://acrabstracts.org/abstract/arhalofenate-acid-inhibits-urate-crystal-induced-inflammatory-responses-through-activation-of-amp-activated-protein-kinase-ampk-signaling/.
  • Poiley J, Steinberg A, Choi Y-J, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheum. 2016;68(8):2027–2034.
  • Steinberg A, Vince B, Choi Y-J, et al. The pharmacodynamics, pharmacokinetics and safety of arhalofenate in combination with febuxostat when treating hyperuricaemia associated with gout. J Rheumatol. 2017;44(3):374–379.
  • Becker M, Schumacher HR, Wortmann R, et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med. 2005;353:2450–2461.
  • Wortmann R, MacDonald P, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386–2397.
  • Khanna D, Khanna P, Fitzgerald J, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–1461.
  • Immune molecular and inflammatory cytokines dysfunction analysis in gout patients with different urate levels. [Cited 2018 Sep 25]. Available from https://clinicaltrials.gov/ct2/show/NCT02060552?term=Diacerein+AND+gout&rank=1 2014
  • A proof-of-concept study of AC-201 to prevent gout flares. [Cited 2018 Sep 25]. Available from https://clinicaltrials.gov/show/NCT01712204 2012
  • Sands E, Kivitz AJ, DeHaan W, et al. Initial phase 2 clinical data of SEL-212 in symptomatic gout patients: monthly dosing of a pegylated uricase (Pegsiticase) with Svp-Rapamycin enables sustained reduction of serum uric acid levels by mitigating formation of anti-drug antibodies [abstract]. Arthritis & rheumatology. 2017 cited 2018 Jan 10;69(suppl 10). Available from. http://acrabstracts.org/abstract/initial-phase-2-clinical-data-of-sel-212-in-symptomatic-goutpatients-monthly-dosing-of-a-pegylated-uricase-pegsiticase-with-svp-rapamycin-enablessustained-reduction-of-serum-uric-acid-levels-by-m/.
  • Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38(3):245–252.
  • Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–1848.
  • Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53.
  • Marchetti C, Swartzwelter B, Koenders M. The human safe NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of experimental arthritis. Ann Rheum Dis. 2017;76:89.
  • Revive therapeutics expands its orphan drug indication pipeline to include cystinuria and Wilson disease. [Cited 2018 Sep 25]. Available from http://www.marketwired.com/press-release/-1995376.htm 2015
  • Akamatsu T, Matsubara T, Saegusa Y, et al. Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug. Rheumatol Int. 1994;13(5):197–201.
  • Bucillamine for the treatment of acute gout flare in subjects with moderate to severe gout. [Cited 2018 Sep 25]. Available from http://clinicaltrials.gov/show/NCT02330796 2014
  • Revive therapeutics announces positive final results from its phase 2a study for the treatment of acute gout flares. [Cited 2018 Sep 25]. Available from http://www.marketwired.com/press-release/revive-therapeutics-announces-positive-final-results-from-its-phase-2a-study-treatment-tsx-venture-rvv-2078040.htm 2015
  • Tan PK, Liu S, Gunic E, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017;7(1):665.
  • VanderLugt J, Gillen M, Yang X, et al. Pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and febuxostat in healthy adult male subjects [abstract]. Arthritis Rheum. 2016 cited 2017 Apr 05;68(suppl 10). Available from. http://acrabstracts.org/abstract/pharmacokinetics-pharmacodynamics-and-tolerability-of-concomitant-multiple-dose-administration-of-verinurad-rdea3170-and-febuxostat-in-healthy-adult-male-subjects/.
  • Gillen M, Miner JN, Pharmacokinetics VS. Pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese male subjects [abstract]. Arthritis Rheum. 2016 cited 2017 May 04;68(suppl 10). Available from. http://acrabstracts.org/abstract/pharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad-a-selective-uric-acid-reabsorption-inhibitor-in-healthy-japanese-male-subjects/.
  • Fleischmann R, Winkle P, Miner JN, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4:E000584.
  • Noveck RJ, Wang Z, Forsthoefel A, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout. [abstract]. Arthritis Rheum. 2012;64(Suppl 10):818.
  • Hatayama M, Sumida C, Kurajoh M, et al. Acute effects of oral tofisopam on plasma concentration and urinary excretion of uric acid and oxypurinol. Curr Clin Pharmacol. 2015;10(2):160-164. doi: 10.2174/1574884710666150126143421.
  • Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, Bcx4208, on the serum uric acid concentrations in patients with gout[abstract]. Arthritis Rheumatism. 2010;62(Suppl 10):150.
  • Becker M, Hollister A, Terkeltaub R, et al. BCX4208 added to allopurinol increases response rates in patients with gout who fail to reach goal range serum uric acid on allopurinol alone: a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2013;71:438.
  • Hollister A, Dobo S, Maetzel A, et al. Long-term safety of BCX4208 added to allopurinol in the chronic management of gout: results of a phase 2 24-week blinded safety extension and vaccine challenge study. Ann Rheum Dis. 2013;71:442–443.
  • Warrell RP Jr., Muindi J, Stevens YW, et al. Induction of profound hypouricemia by a non-sedating thiobarbiturate. Metabolism. 1989;38(6):550–554.
  • Warrell RP Jr., inventorMethods for reducing uric acid levels using barbiturate derivatives. WO 2015073317 A1. USA2015.
  • Phase II Exploratory Clinical Study of KUX-1151 U.S. Department of Health and Human Services: Clinicaltrials.gov; 2015.
  • Ahn S, Ohtomo S, Kiyokawa J, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357:157–166.
  • Taniguchi T, Ashizawa N, Matsumoto K, et al. Enhancement of pharmacological effetcs of uricosuirc agents by conomitant treatment with pyrazinamide in rats. Arch Pharmacol. 2017;390:253–260.
  • Taniguchi T, Ashizawa N, Matsumoto K, et al. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor. J Pharm. 2016;68:76–83.
  • Sands E, Kivitz A, Johnston L, et al. SEL-212: enhanced serum uric acid control in hyperuricemic patients through selective mitigation of anti-drug antibodies against pegsiticase [abstract] THU0422. Ann Rheum Dis. 2017;76(Suppl 2):367.
  • Safety and pharmacodynamics of SEL-037 (Pegsiticase) in subjects with elevated blood uric acid levels. Bethesda, MD: Clinicaltrials.gov; 2016. [Cited 2018 Sep 25]. Available from. https://clinicaltrials.gov/ct2/show/NCT02464605.
  • Warrell RP, Klukovits A, Barnes K, et al. SAT0539 Novel bifunctional inhibitors of xanthine oxidase and URAT1 induce profound hypouricemia in human subjects. Annals of the Rheumatic Diseases. 2014;73:786.
  • Sundy JS, Kitt M. Traniiast, a novel, potential treatment for the chronic management of hyperuricemia In patients with gout, reduces serum uric acid (SUA) in healthy subjects [abstract]. Ann Rheum Dis. 2010;69(Suppl 3):607.
  • Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017;17(2):201–203.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.